Popular Articles

Rigel's R788 Evaluated In Phase 2 Trial In Multiple Cancers
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. This open-label, single arm clinical trial will include patients with advanced colorectal, thyroid, non-small cell lung, hepatocellular, head and neck, or renal cell cancers who have failed to respond to at least one line of therapy.
generic viagra online
FDA Issues Complete Response Letter For INTUNIV™ (guanfacine) Extended Release For The Treatment Of ADHD In Children And Adolescents
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter for INTUNIV TM (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date.
News of the day
New Research Evaluates The Impact Of Working Memory Training And Stimulant Medication On Kids With ADHD
A study to be published in the August 2009 edition of Applied Cognitive Psychology sheds new light on how Cogmed Working Memory Training and stimulant medication address working memory impairments in children with ADHD. Working memory, acknowledged as one of the core deficits in ADHD, represents the brain"s ability to hold and process critical information related to the present moment. This study represents the latest findings from a team of independent UK researchers whose ongoing work examines the impact of Cogmed"s software-based training program on individuals with disorders of memory and attention.
Medical Devices

Report: Health Industry Spends Upwards Of $1.4 Million A Day On Lobbyists

"In a new report released yesterday, the government watchdog group Common Cause found that major health care interests have spent upwards of $1.4 million a day to lobby Capitol Hill so far this year," the National Journal reports. This political spending amount represents a 73 percent increase since 2000. In addition, the report finds that campaign contributions to members of Congress jumped $40 million since 2000, to $94 million in the 2008 election cycle (Krigman, 6/24). Health reform is "a historic confluence of issues that, as a consequence, has the Capitol swarming with lobbyists and awash with money," NPR reports, announcing its new initiative to track influence and lobbying in the health care debate. "These days, just about every interest has a lobbyist. Drug manufacturers, hospitals, doctors, pharmacists, marriage counselors, chiropractors, unions." This year, Congress could actually pass a health system overhaul bill, lobbyists said, so they are attending congressional committee meetings and working the Hill in droves (Overby and Seabrook, 6/25). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):